Semaglutide cuts childhood obesity rates in trial but may stunt growth, study shows
A trial of the weight‑loss drug semaglutide found nearly 40% of children aged six to 11 no longer obese after 68 weeks, while also showing reduced height gain and higher gastrointestinal side effects.
Full story
Read the full story at Kenya Today ↗
Continue reading this story on Kenya Today, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.